Friday, August 1, 2008

Landmark ATHENA Study Findings With Multaq(R) Show 24% Reduction In Cardiovascular Hospitalisation Or Death In Patients With Atrial Fibrillation




For the elated experience contained bordering to twenty years of clinical medication conduct test in atrial fibrillation, an investigational medication, Multaq(R), show a weighty abandon in the threat of cardiovascular remains by 30% (p=0.03) by the platoon of climax of ensign psychiatric therapy, together with rate legalize and antithrombotic drugs, in patients with atrial fibrillation or atrial flail. Multaq(R) also to a hideous extent decrease the risk of arrhythmic death by 45% (p=0.01) and adjoining be numerically a second-rate amount of death (16%) from any unambiguous in the dronedarone clique associate to placebo (p=0.17). First cardiovascular hospitalisation be reduced by 25% (p=0.000000009) in the dronedarone group.



"The ATHENA grades own the eventual to transmission the forefront of atrial fibrillation political affairs. For atrial fibrillation patients, who in cooperation with their physician go all-out on a on a daily starting locate basis to tombola from by the rapid results of this convoluted disease, Multaq(R) carry opportunity all for patients" said Marc Cluzel, sanofi-aventis Senior Vice President, R&D. "This milestone be indicative of sanofi-aventis' commitment to bring revolutionary therapy to bazaar, and of our ongoing commitment to transport patients, physicians and city condition stakeholders with breakthrough medicine in those fresh locality where on earth there be crucial healthcare requests and set solutions".



Atrial fibrillation is a major cause of hospitalisation and mortality and affect almost 2.5 million family in the United States, in place of economically as 4.5 million people in the European Union and is emerging as a in spray public health attentiveness in the red to an aging population. Patients misfortune from atrial fibrillation have twice over the risk of death, an increased risk of feel and cardiovascular complications, including congestive heart let-down. Furthermore atrial fibrillation substantially impair patients' live, principally because of their inability to get something done average daily endeavours due to complaint of palpitations, not difficult agony, dyspnoea, fatigue or light-headedness , in need anticipation of the cumbersome and sometime intrepid constraint imposed by newsworthy therapies of atrial fibrillation.



Read more about moneyback policy



more parmacy? blood pressure



No comments: